Canada markets closed

Acer Therapeutics Inc. (ACER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2000-0.0600 (-2.65%)
At close: 1:00PM EST
2.1500 -0.05 (-2.27%)
After hours: 04:45PM EST

Acer Therapeutics Inc.

One Gateway Center
Suite 351
Newton, MA 02458
United States
844 902 6100

Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher SchellingFounder, Pres, CEO & Director675.8kN/A1976
Mr. Harry S. PalminCOO & CFO535.36kN/A1970
Mr. Donald R. Joseph J.D.Chief Legal Officer & Sec.490.28kN/A1954
Mr. John Michael KloppChief Technical OfficerN/AN/A1975
Mr. John HiltonVP of Marketing & Strategic InsightsN/AN/AN/A
Mr. Bernie PaulVP of HRN/AN/AN/A
Mr. Jefferson E. DavisChief Bus. OfficerN/AN/A1967
Mr. Matthew T. SeibtChief Commercial OfficerN/AN/A1971
Mr. Jason Kneeland CPAVP of Fin. & ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts.

Corporate Governance

Acer Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.